Trial Profile
ORODISPERSIBLE MINITABLETS OF ENALAPRIL IN YOUNG CHILDREN WITH HEART FAILURE DUE TO CONGENITAL HEART DISEASE
Status:
Not yet recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 22 Jul 2022
Price :
$35
*
At a glance
- Drugs Enalapril (Primary)
- Indications Congenital heart defects; Heart failure
- Focus Pharmacokinetics
- Acronyms LENA-WP09
- Sponsors Ethicare GmbH
- 01 Jul 2019 This trial has been Discontinued in UK - MHRA, according to European Clinical Trials Database.
- 01 Jul 2019 This trial has been Discontinued in UK - MHRA, according to European Clinical Trials Database.
- 26 Sep 2018 The trial has been completed in Austria (End Date;2018-05-17).